Cerebrolysin vs Dihexa
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: FPE 1070
Cerebrolysin is not a single peptide but a mixture: a preparation of small peptides and free amino acids made by enzymatically breaking down purified porcine (pig) brain protein, manufactured by EVER Neuro Pharma in Austria. It is given by injection and is approved as a prescription drug in dozens of countries for stroke, traumatic brain injury, and dementia, but it is not FDA-approved in the United States. Despite decades of use abroad, the human evidence remains genuinely contested.
Also: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small synthetic peptide built from angiotensin IV, engineered at Washington State University to be orally active and to cross into the brain. The pitch is bold: it is studied as a procognitive compound that may rebuild synaptic connections, and lab claims of extreme potency made it a darling of the nootropic underground. The reality check: every supporting study is in cells or rodents, there are zero human clinical trials, and a foundational 2012 biochemistry paper describing its target was later retracted.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- Cerebrolysin has stronger research evidence (Human Trials) compared to Dihexa (Animal Studies).
Detailed Comparison
| Attribute | Cerebrolysin | Dihexa |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The proposed idea is that Cerebrolysin's small peptides act like the body's own neurotrophic factors, the molecules such as BDNF and NGF that help neurons survive, grow, and form connections. Researchers hypothesize it engages neurotrophic signaling pathways and may protect neurons from injury and support repair after stroke or brain trauma. It is important to be clear that the exact active components and mechanism are not fully defined, partly because it is a complex biological mixture rather than one purified molecule. So the neurotrophic-mimic story is a plausible hypothesis supported by some lab data, not a precisely mapped pathway. | Dihexa is derived from angiotensin IV, a fragment of the renin-angiotensin system that has long been linked to memory in animal work. The leading hypothesis is that it acts on the hepatocyte growth factor (HGF) and its receptor c-Met, a growth-factor system that drives the formation of new dendritic spines and synapses. In cultured hippocampal neurons, dihexa and related angiotensin IV analogs increase spine density, and that effect disappears when the HGF/c-Met system is blocked, which is the main evidence the pathway matters. It is worth being blunt that the exact molecular interaction has been contested, since the original paper proposing direct HGF binding was retracted, so the mechanism is best treated as a working hypothesis rather than settled fact. |
| Common Dosing | 20-32 mg/day subcutaneous (60mg vial reconstituted in 3 mL bac water = 20 mg/mL) Once or twice daily, split doses above 20 mg into AM/PM, gradual titration | 5-20 mg oral or sublingual daily Once daily, effects can last up to 10 days |
| Administration | Subcutaneous (research) or intravenous/intramuscular (clinical literature) | Oral, sublingual, or intranasal |
| Typical Duration | 8-16 week protocols for research-scale subQ; 10-20 day cycles for clinical IV | Cycles of 2-4 weeks |
| Best Time to Take | Morning | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Cerebrolysin has been tested in many human trials, but the quality and consistency of that evidence is the real story. A Cochrane systematic review on vascular dementia (Cui and colleagues, 2019) concluded that intravenous Cerebrolysin may improve cognition and global function, but cautioned the findings were not definitive because of high risk of bias and heterogeneity across studies. Cochrane reviews of acute ischemic stroke have similarly found insufficient or inconclusive evidence and have flagged a possible signal of increased non-fatal serious adverse events in some analyses. The Alzheimer's Drug Discovery Foundation's Cognitive Vitality review rates the human evidence as mixed and far from conclusive. So while it is a real, widely prescribed drug in many countries, the claim that it reliably improves brain outcomes is not established to Western regulatory standards, and many of the supporting trials come from a narrow set of investigators and sponsors. | The published evidence on dihexa is entirely preclinical. Harding, McCoy and colleagues at Washington State University reported that metabolically stabilized angiotensin IV analogs, including dihexa, restored cognition in scopolamine-impaired and aged rats and stimulated synaptogenesis in cultured neurons (J Pharmacol Exp Ther, 2012 and follow-ups). A 2014 study tied the procognitive and synaptogenic effects of these analogs to the HGF/c-Met system. There are no registered human clinical trials and no published human safety or pharmacokinetic data, so dosing, long-term safety and whether any of the rodent benefit translates to people are all unknown. One important caveat for anyone reading the primary literature: the 2012 paper that first proposed dihexa as an HGF/Met modifier was formally retracted in 2024, which weakens the strongest mechanistic claim. Treat dihexa as an interesting research molecule with promising animal data and a notable evidence gap, not as a proven cognitive enhancer. |
Frequently Asked Questions: Cerebrolysin vs Dihexa
What is the difference between Cerebrolysin and Dihexa?
Cerebrolysin is a cognitive peptide that cerebrolysin is not a single peptide but a mixture: a preparation of small peptides and free amino acids made by enzymatically breaking down purified porcine (pig) brain protein, manufactured by ever neuro pharma in austria. it is given by injection and is approved as a prescription drug in dozens of countries for stroke, traumatic brain injury, and dementia, but it is not fda-approved in the united states. despite decades of use abroad, the human evidence remains genuinely contested. Dihexa is a cognitive peptide that dihexa (n-hexanoic-tyr-ile-(6) aminohexanoic amide) is a small synthetic peptide built from angiotensin iv, engineered at washington state university to be orally active and to cross into the brain. the pitch is bold: it is studied as a procognitive compound that may rebuild synaptic connections, and lab claims of extreme potency made it a darling of the nootropic underground. the reality check: every supporting study is in cells or rodents, there are zero human clinical trials, and a foundational 2012 biochemistry paper describing its target was later retracted. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Cerebrolysin or Dihexa?
Neither is universally "better" - the choice depends on your specific goals. Cerebrolysin is typically used for cognitive purposes, while Dihexa is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Cerebrolysin and Dihexa be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Cerebrolysin and Dihexa together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.